Insider Buying: Boston Scientific (NYSE:BSX) Director Purchases $227,400.00 in Stock

Boston Scientific Corporation (NYSE:BSX) Director Edward Ludwig bought 5,000 shares of the business’s stock in a transaction dated Friday, July 31st. The stock was acquired at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the purchase, the director directly owned 30,359 shares in the company, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

Boston Scientific Stock Performance

Shares of Boston Scientific stock opened at $47.73 on Thursday. The business’s fifty day simple moving average is $45.72 and its 200 day simple moving average is $61.09. The firm has a market capitalization of $69.17 billion, a P/E ratio of 19.32, a price-to-earnings-growth ratio of 1.07 and a beta of 0.56. Boston Scientific Corporation has a 12 month low of $42.20 and a 12 month high of $109.50. The company has a current ratio of 1.24, a quick ratio of 1.22 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter in the previous year, the firm earned $0.75 earnings per share. The business’s revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, analysts anticipate that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific declared that its Board of Directors has authorized a share buyback program on Monday, May 18th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board believes its shares are undervalued.

Institutional Investors Weigh In On Boston Scientific

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Norges Bank bought a new stake in shares of Boston Scientific during the 4th quarter valued at $2,199,395,000. Assenagon Asset Management S.A. boosted its stake in Boston Scientific by 133.6% in the 1st quarter. Assenagon Asset Management S.A. now owns 10,057,936 shares of the medical equipment provider’s stock worth $631,135,000 after purchasing an additional 5,751,760 shares during the period. Janus Henderson Group PLC grew its holdings in Boston Scientific by 31.0% during the 1st quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider’s stock valued at $1,035,202,000 after buying an additional 3,907,981 shares in the last quarter. Maverick Capital Ltd. bought a new stake in shares of Boston Scientific during the fourth quarter valued at about $280,735,000. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in shares of Boston Scientific by 25.9% in the first quarter. Arrowstreet Capital Limited Partnership now owns 13,891,668 shares of the medical equipment provider’s stock worth $871,702,000 after buying an additional 2,856,040 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on BSX. Zacks Research downgraded shares of Boston Scientific from a “hold” rating to a “strong sell” rating in a report on Friday, June 5th. Royal Bank Of Canada reduced their target price on shares of Boston Scientific from $85.00 to $70.00 and set an “outperform” rating for the company in a research report on Thursday, July 30th. Wall Street Zen lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Sunday. Raymond James Financial reaffirmed an “outperform” rating and issued a $57.00 price target on shares of Boston Scientific in a report on Thursday, July 30th. Finally, Wells Fargo & Company reduced their price objective on Boston Scientific from $55.00 to $50.00 and set an “equal weight” rating for the company in a report on Thursday, July 30th. Twenty-four analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $71.62.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.